Loading
A phase 1/2 trial of ALLO-647, Fludarabine and Cyclophosphamide in chronic lymphocytic leukaemia, run by Allogene Therapeutics, active and no longer recruiting.
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) is a phase 1/2 interventional study registered as NCT04416984 by Allogene Therapeutics, with 160 participants enrolled, started 2020-05-21 and due to reach its primary completion in 2029-02. Interventions recorded: ALLO-501A, ALLO-647, Fludarabine and Cyclophosphamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Allogene Therapeutics, Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/